Xeris Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
Xeris Pharmaceuticals has raised $30.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Jun 2026.
Xeris Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Xeris Pharmaceuticals Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Xeris Pharmaceuticals raised $30.0M in a Post-IPO Equity announced in Jan 2022.
4.4 years later, an undisclosed round was announced in Jun 2026 with no disclosed amount.
Xeris Pharmaceuticals Founders and Leadership Team
Contact details for the Xeris Pharmaceuticals team: 1 of 2 have an email address on file.
Start 14-day free trial →Xeris Pharmaceuticals Funding Compared to Other Biotechnology Startups
Funded Startups Like Xeris Pharmaceuticals in Biotechnology and Chicago
Companies Similar to Xeris Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Xeris Pharmaceuticals Funding FAQs
What does Xeris Pharmaceuticals do?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
How much funding has Xeris Pharmaceuticals raised?
Xeris Pharmaceuticals has raised $30.0M across 2 rounds on record.
When did Xeris Pharmaceuticals last raise funding?
Xeris Pharmaceuticals' most recent funding round on record was announced in Jun 2026. The amount was not disclosed.
Who founded Xeris Pharmaceuticals?
FundedIQ lists John Shannon (Founder) at Xeris Pharmaceuticals.
Who is the CEO of Xeris Pharmaceuticals?
Paul Edick is listed as CEO at Xeris Pharmaceuticals.
Where is Xeris Pharmaceuticals headquartered?
Xeris Pharmaceuticals is based in Chicago, Illinois, United States.
How many employees does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals is in the 251-500 employee band.
About FundedIQ's Xeris Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Xeris Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.